Numerous clinical trials evaluate iberdomide (CC-220) from Early Phase 1 to Phase 3, focusing prominently on multiple myeloma across newly diagnosed, relapsed, refractory, and maintenance settings, alongside B-cell non-Hodgkin lymphoma, renal insufficiency, and healthy participants. Research is sponsored by major pharmaceutical corporations and academic medical centers, including Bristol-Myers Squibb, Sanofi, Pfizer, Dana-Farber Cancer Institute, and Mayo Clinic. Recruitment statuses across these investigations encompass active recruiting, completed, enrolling by invitation, active not recruiting, and suspended trials.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06896916 | RECRUITING | Multiple Myeloma |
AbbVie |
2025-08-07 | PHASE1 |
| NCT06892522 | RECRUITING | Multiple Myeloma |
AbbVie |
2025-06-30 | PHASE1; PHASE2 |
| NCT07624513 | NOT_YET_RECRUITING | Multiple Myeloma |
Dana-Farber Cancer Institute |
2026-06-08 | PHASE3 |
| NCT06762769 | RECRUITING | Smouldering Myeloma |
University College, London |
2025-06-02 | PHASE2 |
| NCT06785415 | RECRUITING | Recurrent Multiple Myeloma |
Mayo Clinic |
2025-03-18 | PHASE1; PHASE2 |
| NCT04998786 | ACTIVE_NOT_RECRUITING | Multiple Myeloma at First Relapse |
Nantes University Hospital |
2021-12-14 | PHASE2 |
| NCT06518551 | RECRUITING | Myeloma; Multiple Myeloma; Refractory Multiple Myeloma |
Omar Nadeem, MD |
2024-11-01 | PHASE1; PHASE2 |
| NCT05527340 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
PETHEMA Foundation |
2022-12-15 | PHASE2 |
| NCT07437963 | NOT_YET_RECRUITING | Recurrent Ganglioneuroblastoma; Recurrent Neuroblastoma; Refractory Ganglioneuroblastoma; Refractory Neuroblastoma |
National Cancer Institute (NCI) |
2026-10-28 | PHASE1; PHASE2 |
| NCT05169515 | ACTIVE_NOT_RECRUITING | Non-Hodgkin Lymphoma |
Hoffmann-La Roche |
2022-10-26 | PHASE1 |
| NCT07601100 | NOT_YET_RECRUITING | Newly Diagnosed Multiple Myeloma |
Dana-Farber Cancer Institute |
2026-09-03 | PHASE1; PHASE2 |
| NCT05827016 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Bristol-Myers Squibb |
2023-06-22 | PHASE3 |
| NCT05896228 | RECRUITING | Refractory Multiple Myeloma; Relapsed Multiple Myeloma |
Benjamin T Diamond, MD |
2024-02-20 | PHASE2 |
| NCT04884035 | ACTIVE_NOT_RECRUITING | Lymphoma, B-Cell |
Celgene |
2021-09-15 | PHASE1 |
| NCT06216158 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
University of Heidelberg Medical Center |
2024-04-05 | PHASE3 |
| NCT06121843 | RECRUITING | Multiple Myeloma |
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
2024-02-22 | PHASE1 |
| NCT05434689 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
University of Alabama at Birmingham |
2023-01-18 | PHASE1; PHASE2 |
| NCT05583617 | RECRUITING | Multiple Myeloma |
Hoffmann-La Roche |
2023-11-14 | PHASE1; PHASE2 |
| NCT06232044 | SUSPENDED | Recurrent Multiple Myeloma; Refractory Multiple Myeloma |
Alliance for Clinical Trials in Oncology |
2025-04-23 | PHASE1; PHASE2 |
| NCT05272826 | RECRUITING | Multiple Myeloma |
Canadian Myeloma Research Group |
2024-12-12 | PHASE2 |
| NCT06107738 | RECRUITING | Multiple Myeloma |
Barbara Ann Karmanos Cancer Institute |
2023-12-21 | PHASE2 |
| NCT04392037 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Amsterdam UMC, location VUmc |
2021-02-17 | PHASE2 |
| NCT04975997 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Celgene |
2022-06-23 | PHASE3 |
| NCT06179888 | SUSPENDED | Multiple Myeloma |
National Cancer Institute (NCI) |
2024-08-27 | PHASE2 |
| NCT04776395 | RECRUITING | Smoldering Plasma Cell Myeloma |
Emory University |
2021-07-09 | PHASE2 |
| NCT06348108 | RECRUITING | Multiple Myeloma; Refractory Multiple Myeloma; Relapsed Multiple Myeloma |
Alfred Chung, MD |
2025-07-28 | PHASE1 |
| NCT07727668 | NOT_YET_RECRUITING | Multiple Myeloma; Relapsed/Refractory Multiple Myeloma |
Shambavi Richard |
2026-07 | EARLY_PHASE1 |
| NCT05354557 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Memorial Sloan Kettering Cancer Center |
2022-04-26 | PHASE2 |
| NCT06215118 | RECRUITING | Multiple Myeloma |
Pfizer |
2024-02-20 | PHASE1 |
| NCT05558319 | RECRUITING | Newly Diagnosed Multiple Myeloma |
PETHEMA Foundation |
2022-11-10 | PHASE3 |
| NCT05199311 | SUSPENDED | Multiple Myeloma |
Hackensack Meridian Health |
2022-05-13 | PHASE1; PHASE2 |
| NCT06465316 | RECRUITING | Recurrent Multiple Myeloma; Refractory Multiple Myeloma |
National Cancer Institute (NCI) |
2024-12-06 | PHASE1 |
| NCT05560399 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Icahn School of Medicine at Mount Sinai |
2023-02-06 | EARLY_PHASE1 |
| NCT05392946 | ACTIVE_NOT_RECRUITING | Plasma Cell Myeloma |
Mayo Clinic |
2022-08-11 | PHASE1; PHASE2 |
| NCT04882163 | WITHDRAWN | Lymphoma, B-Cell |
Celgene |
2021-10-10 | PHASE1; PHASE2 |
| NCT05177536 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
University of Nebraska |
2022-06-14 | PHASE2 |
| NCT04855136 | TERMINATED | Multiple Myeloma |
Celgene |
2021-06-01 | PHASE1 |
| NCT02773030 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Celgene |
2016-10-14 | PHASE1; PHASE2 |
| NCT06216158 | Recruiting | Multiple Myeloma |
University of Heidelberg Medical Center|KKS Netzwerk|Wuerzburg University Hospital|Sanofi|Bristol-Myers Squibb |
2024-04-05 | Phase 3 |
| NCT06215118 | Recruiting | Multiple Myeloma |
Pfizer|Bristol-Myers Squibb |
2024-02-20 | Phase 1 |
| NCT05289492 | TERMINATED | Multiple Myeloma |
iTeos Therapeutics |
2022-05-01 | PHASE1 |
| NCT04564703 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Stichting European Myeloma Network |
2021-02-22 | PHASE2 |
| NCT05899738 | COMPLETED | Healthy Volunteers |
Bristol-Myers Squibb |
2023-05-18 | PHASE1 |
| NCT05827016 | Recruiting | Multiple Myeloma |
Bristol-Myers Squibb |
2023-06-22 | Phase 3 |
| NCT03310619 | COMPLETED | Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular |
Celgene |
2017-12-20 | PHASE1; PHASE2 |
| NCT05560399 | Enrolling by invitation | Multiple Myeloma |
Icahn School of Medicine at Mount Sinai|Multiple Myeloma Research Consortium|Bristol-Myers Squibb |
2023-02-06 | Early Phase 1 |
| NCT04464798 | TERMINATED | Lymphoma |
Celgene |
2020-11-11 | PHASE1 |
| NCT04933747 | COMPLETED | Renal Insufficiency |
Celgene |
2021-08-12 | PHASE1 |
| NCT03161483 | COMPLETED | Lupus Erythematosus, Systemic |
Celgene |
2017-08-31 | PHASE2 |
| NCT03824678 | COMPLETED | Hepatic Impairment; Healthy Volunteers |
Celgene |
2019-02-13 | PHASE1 |
| NCT02185040 | COMPLETED | Systemic Lupus Erythematosus |
Celgene |
2014-09-16 | PHASE2 |
| NCT03294603 | COMPLETED | Healthy Volunteer |
Celgene |
2017-09-11 | PHASE1 |
| NCT02192489 | WITHDRAWN | Sarcoidosis |
Celgene |
2014-11-01 | PHASE2 |
| NCT03135509 | COMPLETED | Healthy Volunteers |
Celgene |
2017-05-24 | PHASE1 |
| NCT02820935 | COMPLETED | Pharmacokinetics |
Celgene Corporation |
2016-07 | PHASE1 |
| NCT02034773 | COMPLETED | Healthy Volunteers |
Celgene Corporation |
2013-05 | PHASE1 |
| NCT01733875 | COMPLETED | Healthy |
Celgene |
2012-11-01 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-05-12)
Check the
Iberdomide (CC-220)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Iberdomide (CC-220) Solubility in DMSO
- Iberdomide (CC-220) Stock Solution
- Iberdomide (CC-220) Storage
- Iberdomide (CC-220) Stability
- Iberdomide (CC-220) Molecular Weight
- Iberdomide (CC-220) SMILES
- Iberdomide (CC-220) CAS Number
- Iberdomide (CC-220) Chemical Structure (2D and 3D)
- Iberdomide (CC-220) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.